Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Short Interest Up 6.0% in September

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 371,600 shares, an increase of 6.0% from the September 15th total of 350,500 shares. Based on an average daily trading volume, of 214,600 shares, the days-to-cover ratio is currently 1.7 days. Currently, 2.9% of the company’s shares are short sold.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Headlands Technologies LLC lifted its stake in Eagle Pharmaceuticals by 75.7% in the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 2,861 shares in the last quarter. Creative Planning acquired a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at about $59,000. Mackenzie Financial Corp purchased a new stake in shares of Eagle Pharmaceuticals in the second quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eagle Pharmaceuticals during the second quarter worth approximately $65,000. Finally, Fidelis Capital Partners LLC purchased a new position in Eagle Pharmaceuticals during the second quarter valued at approximately $71,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Stock Down 18.8 %

Shares of NASDAQ:EGRX opened at $0.65 on Friday. The company’s fifty day moving average is $3.49 and its two-hundred day moving average is $4.26. The company has a market cap of $8.44 million, a P/E ratio of 0.55 and a beta of 0.51. Eagle Pharmaceuticals has a 12-month low of $0.10 and a 12-month high of $14.78.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Eagle Pharmaceuticals in a research report on Saturday, October 12th. They issued a “hold” rating on the stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.